Skip to main content
. 2020 Jun 29;9(7):2033. doi: 10.3390/jcm9072033

Table 5.

Management of hypothyroidism induced by immune checkpoint inhibitors.

CTCAE Grade Management Treatment of Adverse Event
Grade 1
  • Continue ICI treatment

  • Continue to monitor TSH, FT3, and FT4 levels every 2–3 weeks

Grade 2
  • Stop ICI treatment until the symptoms ameliorate or test values become normal

  • After amelioration of symptoms, resume administration of ICI

  • Consult an endocrinologist

  • Start thyroid hormone replacement therapy if symptoms are present or the TSH level is high

  • If thyroid function is stable, perform a thyroid function test every 6 weeks

Grade 3 or 4
  • Same as above

  • Consult an endocrinologist

  • Start administration of β-blocker

  • In case of myxedema coma, treat the patient in the intensive care unit

  • Following stabilization of symptoms, treat as per the protocol for Grade 2 events

CTCAE, Common Terminology Criteria for Adverse Events; ICI, immune checkpoint inhibitor; TSH, thyroid-stimulating hormone; FT4, free T4; FT3, free T3.